Klinikum Frankfurt Hoechst GmbH — Clinical Trial Site

27 Registered trials

14 Currently recruiting

Organisation

Klinikum Frankfurt Hoechst GmbH

Location

Frankfurt Am Main, Germany

Identifier

ORG-100037724

Address

Gotenstrasse 6-8, Hoechst, 65929, Germany

Departments

049006: Gynäkologie
Clinic for Gynecology and Obstetrics
Clinic for Internal medicine, haematology and oncology
Gynäkologie
Gynecology and Obstetrics
Hematology
Kardiologisches Studienzentrum
Klinik für Gynäkologie
Klinik für Gynäkologie und Geburtshilfe
Klinik für Innere Medizin 3 (Hämatologie, Onkologie, Palliativmedizin)
Klinik für Innere Medizin III
Klinik für Neurologie
Klinik für Pneumologie, Beatmungsmedizin/Weaning, Thoraxonkologie und Schlafmedizin
N/A
Oncology
Onkologie
Retrieving data. Wait a few seconds and try to cut or copy again.

Clinical trials at this site (27)

Search interface

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Recruiting

2022-501890-38-00 acute ischemic stroke 4 2024-02-16
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants Recruiting

2025-521762-99-00 acute ischemic stroke 5 2026-03-09
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Non-small cell lung cancer 5 2026-03-05
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting

2025-521260-35-00 acute ischemic stroke and atrial fibrillation (AF) 6 2025-11-07
Recombinant coagulation Factor VIIa administered at the earliest time for the treatment of stroke caused by bleeding in the brain - FASTEST… Recruiting

2024-517383-28-00 Acute haemorrhagic stroke 5 2025-07-21
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer-… Recruiting

2023-509292-17-00 primary high-risk lobular breast cancer 4 2024-11-08
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14
„INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion prot… Ended

2024-516026-56-00 Histologically confirmed locally advanced or metastatic 3 2017-08-17
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27